Arthur Tzianabos - Net Worth and Insider Trading
Arthur Tzianabos Net Worth
The estimated net worth of Arthur Tzianabos is at least $385,247 dollars as of 2024-11-05. Arthur Tzianabos is the Director of Q32 Bio Inc and owns about 7,983 shares of Q32 Bio Inc (QTTB) stock worth over $378,554. Arthur Tzianabos is the Director of Homology Medicines Inc and owns about 7,154 shares of Homology Medicines Inc (FIXX) stock worth over $6,687. Arthur Tzianabos is also the President and CSO of Millendo Therapeutics Inc and owns about 6 shares of Millendo Therapeutics Inc (MLND) stock worth over $6. Besides these, Arthur Tzianabos also holds Stoke Therapeutics Inc (STOK) . Details can be seen in Arthur Tzianabos's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Arthur Tzianabos has not made any transactions after 2024-03-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Arthur Tzianabos
Arthur Tzianabos Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Arthur Tzianabos owns 6 companies in total, including Akouos Inc (AKUS) , Stoke Therapeutics Inc (STOK) , and Homology Medicines Inc (FIXX) among others .
Click here to see the complete history of Arthur Tzianabos’s form 4 insider trades.
Insider Ownership Summary of Arthur Tzianabos
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
AKUS | Akouos Inc | 2020-06-25 | director |
STOK | Stoke Therapeutics Inc | 2021-02-19 | director |
FIXX | Homology Medicines Inc | 2024-01-09 | director & President & CEO |
2016-08-26 | director | ||
2015-12-03 | President and CSO | ||
2013-09-03 | Chief Scientific Officer |
Arthur Tzianabos Latest Holdings Summary
Arthur Tzianabos currently owns a total of 4 stocks. Among these stocks, Arthur Tzianabos owns 7,983 shares of Q32 Bio Inc (QTTB) as of March 25, 2024, with a value of $378,554 and a weighting of 98.26%. Arthur Tzianabos owns 7,154 shares of Homology Medicines Inc (FIXX) as of January 9, 2024, with a value of $6,687 and a weighting of 1.74%. Arthur Tzianabos also owns 6 shares of Millendo Therapeutics Inc (MLND) as of April 9, 2015, with a value of $6 and a weighting of 0%. The other 1 stocks Stoke Therapeutics Inc (STOK) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Arthur Tzianabos
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
QTTB | Q32 Bio Inc | 2024-03-25 | 7,983 | 47.42 | 378,554 |
FIXX | Homology Medicines Inc | 2024-01-09 | 7,154 | 0.93 | 6,687 |
MLND | Millendo Therapeutics Inc | 2015-04-09 | 6 | 1.06 | 6 |
STOK | Stoke Therapeutics Inc | 2021-02-19 | 0 | 12.61 | 0 |
Holding Weightings of Arthur Tzianabos
Arthur Tzianabos Form 4 Trading Tracker
According to the SEC Form 4 filings, Arthur Tzianabos has made a total of 1 transactions in Q32 Bio Inc (QTTB) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Q32 Bio Inc is the sale of 265 shares on March 25, 2024, which brought Arthur Tzianabos around $6,413.
According to the SEC Form 4 filings, Arthur Tzianabos has made a total of 6 transactions in Homology Medicines Inc (FIXX) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Homology Medicines Inc is the sale of 724 shares on January 9, 2024, which brought Arthur Tzianabos around $7,431.
According to the SEC Form 4 filings, Arthur Tzianabos has made a total of 0 transactions in Millendo Therapeutics Inc (MLND) over the past 5 years. The most-recent trade in Millendo Therapeutics Inc is the acquisition of 1 shares on April 9, 2015, which cost Arthur Tzianabos around $6,473.
More details on Arthur Tzianabos's insider transactions can be found in the Insider Trading History of Arthur Tzianabos table.Insider Trading History of Arthur Tzianabos
- 1
Arthur Tzianabos Trading Performance
GuruFocus tracks the stock performance after each of Arthur Tzianabos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arthur Tzianabos is -10.16%. GuruFocus also compares Arthur Tzianabos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Arthur Tzianabos within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Arthur Tzianabos's insider trading performs compared to the benchmark.
Performance of Arthur Tzianabos
Arthur Tzianabos Ownership Network
Ownership Network List of Arthur Tzianabos
Ownership Network Relation of Arthur Tzianabos
Arthur Tzianabos Owned Company Details
What does Akouos Inc do?
Who are the key executives at Akouos Inc?
Arthur Tzianabos is the director of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .
Akouos Inc (AKUS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Akouos Inc Insider Transactions
Arthur Tzianabos Mailing Address
Above is the net worth, insider trading, and ownership report for Arthur Tzianabos. You might contact Arthur Tzianabos via mailing address: C/o Homology Medicines, Inc., One Patriots Park, Bedford Ma 01730.